PharmaCyte Biotech (PMCB) Current Assets (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Current Assets of $37.4 million for Q2 2026, up 67.24% year-over-year from $22.4 million in Q2 2025, and up 80.81% quarter-over-quarter from $20.7 million in Q1 2026.
PharmaCyte Biotech (PMCB) Current Assets (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Current Assets for 16 consecutive years, with $37.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets rose 67.24% year-over-year to $37.4 million; the TTM figure through Apr 2026 stood at $37.4 million (up 67.24% YoY), while the FY2026 annual figure was $37.4 million, up 67.24% from the prior year.
- Current Assets rose to $37.4 million in Q2 2026 per PMCB's latest filing, from $20.7 million in the prior quarter.
- Across five years, Current Assets topped out at $86.8 million in Q1 2022 and bottomed at $17.0 million in Q1 2025.
- Historically, Current Assets has averaged $51.5 million across 5 years, with a median of $56.0 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets soared 5353.31% — and 2025, when it tumbled 72.42%.
- PharmaCyte Biotech's Current Assets stood at $77.2 million in 2022, then fell by 4.49% to $73.7 million in 2023, then tumbled by 71.07% to $21.3 million in 2024, then advanced by 7.92% to $23.0 million in 2025, then surged by 62.54% to $37.4 million in 2026.
- Business Quant data shows PMCB's Current Assets at $37.4 million in Q2 2026, $20.7 million in Q1 2026, and $23.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 37.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 37.42 Mn |
| Jan 31, 2026 | 20.70 Mn |
| Oct 31, 2025 | 23.02 Mn |
| Jul 31, 2025 | 19.11 Mn |
| Apr 30, 2025 | 22.38 Mn |
| Jan 31, 2025 | 16.96 Mn |
| Oct 31, 2024 | 21.33 Mn |
| Jul 31, 2024 | 32.88 Mn |
| Apr 30, 2024 | 50.44 Mn |
| Jan 31, 2024 | 61.51 Mn |
| Oct 31, 2023 | 73.75 Mn |
| Jul 31, 2023 | 74.75 Mn |
| Apr 30, 2023 | 68.15 Mn |
| Jan 31, 2023 | 72.82 Mn |
| Oct 31, 2022 | 77.22 Mn |
| Jul 31, 2022 | 82.26 Mn |
| Apr 30, 2022 | 85.49 Mn |
| Jan 31, 2022 | 86.81 Mn |
| Oct 31, 2021 | 87.18 Mn |
| Jul 31, 2021 | 1.51 Mn |